The company operates through four segments: Cell Therapies; Developing New Anti-Cancer Drugs; E-commerce Platform for Pharmaceutical and Healthcare Products; and Detection & Diagnosis of Infectious Diseases. Beroni has operations in Australia, United States, China and Japan.
Cyborg Score Rationale
Beroni operates in high-growth biopharmaceutical and diagnostic markets but trades as a penny stock (OTC at $0.0064 as of March 2026) with minimal market capitalization (~$180K). The company has diversified assets including FDA-approved diagnostics and development programs, but faces significant liquidity and visibility challenges as a micro-cap entity.
Top Insights
Operates across four distinct business segments spanning cell therapies, oncology drug development, pharmaceutical e-commerce, and infectious disease diagnostics
Holdings include NicoBloc (smoking cessation), FDA-approved COVID-19 diagnostic kits, and stem-cell based cosmetics
Geographic footprint spans four major markets: Australia (HQ), United States, China, and Japan
Micro-cap OTC listing with minimal trading volume and market visibility despite diversified asset portfolio
Named Competitors
Diagnostic Kits & Tests — Rapid diagnostic and testing solutions